Name: Lu Qiao
Email: qiao.lu@@sjtu.edu.cn
Research Interest: Antigen presentation and Immune evasion
Personal Introduction:
Dr. Lu obtained his Ph.D. degree from Yale University in 2018 and conducted his postdoctoral research at New York University School of Medicine. He is now a Principal Investigator at the Shanghai Institute of Immunology Shanghai Jiao Tong University School of Medicine.
His research focuses on antigen presentation, particularly on antigen presentation mediated by major histocompatibility complex class I (MHC-I), which is crucial for activating specific T cell immune responses and establishing immune surveillance and functions as a bridge between innate and adaptive immunity. Just as the central dogma of "DNA → RNA → protein" laid the foundation for molecular genetics, the process of "antigen-presenting cells (APC) → T cells → target cells" forms the central dogma of immunology. However, tumor cells and pathogens have evolved various strategies to suppress antigen presentation and achieve immune evasion—this is also a key factor to cause resistance to immunotherapy. Therefore, exploring the regulatory mechanisms of antigen presentation in disease microenvironments will help us understand disease pathogenesis and promote the development of novel therapeutic strategies. By utilizing innovative screening platforms, combined with molecular and cellular biology, biochemistry, and various mouse models, Dr. Lu aims to deeply explore the regulatory mechanisms of classical antigen presentation and cross-presentation in tumor and other disease microenvironments, and use this as a foundation for the development of innovative therapies.
Dr. Lu has published several high-quality papers as the first or co-first author in prestigious journals such as Cell, Immunity, Nature Communications, and Nano Letters. He has also received the Cancer Research Institute Irvington Postdoctoral Fellowship. Dr. Lu currently serves on the editorial boards of Cancer Insight and Biosensors and Biomedical Materials, and acts as the external reviewer for multiple academic journals.
Grants:
09/2024-10/2030
Shanghai Jiaotong University School of Medicine Startup Grant
Role: Principal Investigator
Publications
Research articles:
Lu Q*, Liu J*, Zhao S*, Gomez Castro MF, Laurent-Rolle M, Dong J, Ran X, Damani-Yokota P, Tang H, Karakousi T, Son J, Kaczmarek ME, Zhang Z, Yeung ST, McCune BT, Chen RE, Tang F, Ren X, Chen X, Hsu JCC, Teplova M, Huang B, Deng H, Long Z, Mudianto T, Jin S, Lin P, Du J, Zang R, Su TT, Herrera A, Zhou M, Yan R, Cui J, Zhu J, Zhou Q, Wang T, Ma J, Koralov SB, Zhang Z, Aifantis I, Segal LN, Diamond MS, Khanna KM, Stapleford KA, Cresswell P, Liu Y, Ding S, Xie Q, Wang J. SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2. Immunity. 2021 Jun 8;54(6):1304-1319.e9. PMCID: PMC8106883. *Equal contribution.
Chen X*, Lu Q*, Zhou H, Liu J, Nadorp B, Lasry A, Sun Z, Lai B, Rona G, Zhang J, Cammer M, Wang K, Al-Santli W, Ciantra Z, Guo Q, You J, Sengupta D, Boukhris A, Zhang H, Liu C, Cresswell P, Dahia PLM, Pagano M, Aifantis I, Wang J. A membrane-associated MHC-I inhibitory axis for cancer immune evasion. Cell. 2023 Aug 31;186(18):3903-3920.e21. Epub 2023 Aug 8. PMID: 37557169. *Equal contribution.
Lu Q, Grotzke JE, Cresswell P. A novel probe to assess cytosolic entry of exogenous proteins. Nat Commun. 2018 Aug 6;9(1):3104. PMCID: PMC6079096.
Jiang Y*, Lu Q*, Wang Y*, Xu E, Ho A, Singh P, Wang Y, Jiang Z, Yang F, Tietjen GT, Cresswell P, Saltzman WM. Quantitating Endosomal Escape of a Library of Polymers for mRNA Delivery. Nano Lett. 2020 Feb 12;20(2):1117-1123. PMCID: PMC7195212. *Equal contribution.
Grotzke JE, Lu Q, Cresswell P. Deglycosylation-dependent fluorescent proteins provide unique tools for the study of ER-associated degradation. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3393-8. PMCID: PMC3587246.
He K, Wan T, Wang D, Hu J, Zhou T, Tao W, Wei Z, Lu Q, Zhou R, Tian Z, Flavell RA, Zhu S. Gasdermin D licenses MHCII induction to maintain food tolerance in small intestine. Cell. 2023 Jul 6;186(14):3033-3048.e20. Epub 2023 Jun 15. PMID: 37327784.
Hu W, Zhang Y, Fei P, Zhang T, Yao D, Gao Y, Liu J, Chen H, Lu Q, Mudianto T, Zhang X, Xiao C, Ye Y, Sun Q, Zhang J, Xie Q, Wang PH, Wang J, Li Z, Lou J, Chen W. Mechanical activation of spike fosters SARS-CoV-2 viral infection. Cell Res. 2021 Aug 31; PMCID: PMC8406658. Impact factor: 46.3
Silberstein JL, Du J, Chan KW, Frank JA, Mathews II, Kim YB, You J, Lu Q, Liu J, Philips EA, Liu P, Rao E, Fernandez D, Rodriguez GE, Kong XP, Wang J, Cochran JR. Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function. Proc Natl Acad Sci U S A. 2024 Mar 19;121(12):e2310866121. doi: 10.1073/pnas.2310866121. Epub 2024 Mar 14. PMID: 38483996; PMCID: PMC10962948.
Review articles:
Wang J*, Lu Q*, Chen X*, Aifantis I. Targeting MHC-I inhibitory pathways for cancer immunotherapy. Trends Immunol. 2024 Mar;45(3):177-187. Epub 2024 Mar 2. PMID: 38433029. *Equal contribution.
Grotzke JE, Sengupta D, Lu Q, Cresswell P. The ongoing saga of the mechanism(s) of MHC class I-restricted cross-presentation. Curr Opin Immunol. 2017 Jun;46:89-96. PMCID: PMC5554740.
Sun J, Lu Q, Sanmamed MF, Wang J. Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy. Clin Cancer Res. 2021 Feb 1;27(3):680-688. PubMed ID: 32958700.
Gu R, Mao T, Lu Q, Su T, Wang J. Myeloid dysregulation and therapeutic intervention in COVID-19. Semin Immunol. 2021. 2021 Nov 9:101524. PMID: 34823995.
Patents:
Targeting SARS-CoV-2 viral-immune interaction for COVID-19 therapy (US20220089695A1)
Targeting MHC-I antigen presentation modulators for immunotherapy for cancer and autoimmune disorders (WO2024156006A2).